Advertisement
Journal of Clinical Oncology  
Search for:
Limit by:
  Browse by Subject or Issue
Home Search or Browse JCO My JCO Subscriptions Customer Service Site Map

This Article
Right arrow Full Text
Right arrow Full Text (PDF)
Right arrow Purchase Article
Right arrow View Shopping Cart
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Services
Right arrow Email this article to a colleague
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Save to my personal folders
Right arrow Download to citation manager
Right arrowRights & Permissions
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Bonner, J. A.
Right arrow Articles by Waksal, H. W.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Bonner, J. A.
Right arrow Articles by Waksal, H. W.
Social Bookmarking
 Add to CiteULike   Add to Complore   Add to Connotea   Add to Del.icio.us   Add to Digg   Add to Facebook   Add to Reddit   Add to Technorati   Add to Twitter  
What's this?
Journal of Clinical Oncology, Vol 18, No 21S (November 1 Supplement) 2000: 47s-53s
© 2000 American Society for Clinical Oncology


INTEGRATED SYMPOSIUM

Enhanced Apoptosis With Combination C225/Radiation Treatment Serves as the Impetus for Clinical Investigation in Head and Neck Cancers

By James A. Bonner, Kevin P. Raisch, Hoa Q. Trummell, Francisco Robert, Ruby F. Meredith, Sharon A. Spencer, Donald J. Buchsbaum, Mansoor N. Saleh, Murray A. Stackhouse, Albert F. LoBuglio, Glenn E. Peters, William R. Carroll, Harlan W. Waksal

From the University of Alabama at Birmingham, Comprehensive Cancer Center (Experimental Therapeutics Program), Birmingham, AL, and ImClone Systems, Inc, Somerville, NJ.

Address reprint requests to James A. Bonner, MD, Department of Radiation Oncology, University of Alabama at Birmingham, 1530 3rd Ave South, WTI 105, Birmingham, AL 35294-3300.

PURPOSE: Epidermal growth factor receptor (EGFr) is overexpressed in a majority of head and neck squamous cell carcinomas, and this overexpression is associated with a poor prognosis. Therefore, EGFr has become the target of investigations aimed at disabling the receptor to determine whether this process leads to improved tumor kill with conventional treatment.

MATERIALS AND METHODS: C225 is an anti-EGFr monoclonal antibody that inhibits receptor activity by blocking the ligand binding site. A panel of human head and neck squamous cell carcinoma cell lines was used to study the combination of C225 and radiation.

RESULTS: It was determined that the combination of C225 (5 µg/mL) delivered simultaneously with radiation (3 Gy) resulted in a greater decrement in cellular proliferation than either treatment alone. This reduction in proliferation correlated with reduced EGFr tyrosine phosphorylation and a reduction in phosphorylated signal transducer and activator of transcription-3 (STAT-3) protein (known to protect cells from apoptosis). Also, the decrement in proliferation correlated with increased apoptotic events, thereby indirectly linking C225/radiation–induced regulation of STAT-3 protein to apoptosis.

CONCLUSION: This preclinical work serves as important support for the ongoing clinical investigation of C225 and radiotherapy for patients with head and neck carcinomas. The initial results of these clinical studies have been promising.

J.A.B. receives financial reimbursement as a consultant to Imclone Systems, Inc.


Add to CiteULike CiteULike   Add to Complore Complore   Add to Connotea Connotea   Add to Del.icio.us Del.icio.us   Add to Digg Digg   Add to Facebook Facebook   Add to Reddit Reddit   Add to Technorati Technorati   Add to Twitter Twitter    What's this?


This article has been cited by other articles:


Home page
The OncologistHome page
K. K. Ang
Multidisciplinary Management of Locally Advanced SCCHN: Optimizing Treatment Outcomes
Oncologist, August 1, 2008; 13(8): 899 - 910.
[Abstract] [Full Text] [PDF]


Home page
Arch Otolaryngol Head Neck SurgHome page
M. J. Worsham, K. M. Chen, N. Tiwari, G. Pals, J. P. Schouten, S. Sethi, and M. S. Benninger
Fine-mapping loss of gene architecture at the CDKN2B (p15INK4b), CDKN2A (p14ARF, p16INK4a), and MTAP genes in head and neck squamous cell carcinoma.
Arch Otolaryngol Head Neck Surg, April 1, 2006; 132(4): 409 - 415.
[Abstract] [Full Text] [PDF]


Home page
JNMHome page
N. R. Schechter, R. E. Wendt III, D. J. Yang, A. Azhdarinia, W. D. Erwin, A. M. Stachowiak, L. D. Broemeling, E. E. Kim, J. D. Cox, D. A. Podoloff, et al.
Radiation Dosimetry of 99mTc-Labeled C225 in Patients with Squamous Cell Carcinoma of the Head and Neck
J. Nucl. Med., October 1, 2004; 45(10): 1683 - 1687.
[Abstract] [Full Text] [PDF]


Home page
Cancer Res.Home page
A. Chakravarti, A. Chakladar, M. A. Delaney, D. E. Latham, and J. S. Loeffler
The Epidermal Growth Factor Receptor Pathway Mediates Resistance to Sequential Administration of Radiation and Chemotherapy in Primary Human Glioblastoma Cells in a RAS-dependent Manner
Cancer Res., August 1, 2002; 62(15): 4307 - 4315.
[Abstract] [Full Text] [PDF]


Home page
Cancer Res.Home page
A. Chakravarti, J. S. Loeffler, and N. J. Dyson
Insulin-like Growth Factor Receptor I Mediates Resistance to Anti-Epidermal Growth Factor Receptor Therapy in Primary Human Glioblastoma Cells through Continued Activation of Phosphoinositide 3-Kinase Signaling
Cancer Res., January 1, 2002; 62(1): 200 - 207.
[Abstract] [Full Text] [PDF]



About
JCO
 Editorial
Roster
 Advertising
Information
 Librarians &
Institutions
 Rights &
Permissions
 PDA Services

Copyright © 2000 by the American Society of Clinical Oncology, Online ISSN: 1527-7755. Print ISSN: 0732-183X
Terms and Conditions of Use
  HighWire Press HighWire Press™ assists in the publication of JCO Online